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ABSTRACT
Dupuytren disease is highly prevalent and the
finger contractures can be very extensile,
compromising the patients’ hand function. To
restore full function, contractures have been
addressed by cutting the causative strands for
nearly 200 years, ever since Baron Guillaume
Dupuytren demonstrated his technique at the
beginning of the nineteenth century. Surgery
can be minimal (fasciotomy) or quite invasive
(fasciectomy and even skin replacement).
However, in the last decade translational
research has introduced the non-surgical
technique of enzymatic fasciotomy with
collagenase injections. Now, finger
contractures can be released with single
injections on monthly intervals, to address
one joint contracture at a time. However, in
hands affected with Dupuytren contractures to
the extent that the patient calls for treatment,
most often more than one joint is involved. In
surgical treatment options all contracted joints
are addressed in a single procedure.
Nevertheless, extensile surgery withholds
inherent risks of complications and intense
rehabilitation. Today, the minimally-invasive
method with enzymatic fasciotomy by
collagenase injection has demonstrated
reliable outcomes with few morbidities and
early recovery. However, single-site injection is
todays’ standard procedure and multiple joints
are addressed in several sessions with monthly
intervals. This triggers a longer recovery and
treatment burden in severely affected hands
even though surgery is avoided. Therefore,
further treatment modalities of collagenase use
are explored. Adjustments in the treatment
regimes’ flexibility and collagenase injections
addressing more than one joint contracture
simultaneously will improve the burden of
multiple sessions and, therefore, enzymatic
fasciotomy may become the preferred method
in more extensile Dupuytren contractures. In
this independent review, the challenge of
Dupuytren disease affecting a single versus
multiple joints is presented. The pros and cons
of collagenase use are weighed, founded by the
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available scientific background. The demands
and options for collagenase in future treatment
regimens for extensile Dupuytren contractures
are discussed.
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INTRODUCTION
Dupuytren contracture is a highly prevalent
hand affection in which contracted fingers
compromise hand function. In a recent
meta-analysis prevalence up to 30% in the
Western countries was reported, increasing
with age [24]. Asymptomatic palmar fibrosis is
more common than overt contractures, which
require treatment [15]. The standard treatment
has been fasciotomy or fasciectomy ever since
Baron Guillaume Dupuytren introduced cutting
the strands in his the public sessions at the
Hotel Dieu in Paris in 1831 [1]. Since then, the
pathology has been extensively studied, with
historical milestones as the histology stages of
Luck in 1959 [27] the identification of the
myofibroblast by Gabbiani in 1972 [18]. It is
the collagen production of these myofibroblast
that holds the finger contractures. This collagen
is found more in the cords than in the nodules,
which contain mostly myofibroblasts [46]. Both
are the targets of surgical treatment: either the
cords are cut (fasciotomy) or all of the
pathological tissue including nodules is
removed (fasciectomy).
Since the cords are collagen rich,
understandably the collagenase enzyme has
been the topic of research for eventual clinical
purposes. Even as long ago as 1971, Hueston
[22] instigated the first clinical attempts with
enzyme injections. The last decade has become
the era of the clinical introduction of
clostridium collagenase use in the Dupuytren
contracture, after the first successful in vitro
report in 1996 [43] and the first clinical
open-label study of 35 patients in 2000 [4].
Today’s collagenase use is the translational
result of many years of basic research and is an
example of how surgically treated affections can
become treatable or rather controllable without
operation.
In this independent review, the focus lies on
the urge to extend the collagenase treatment
regimen to meet current shortcomings in
extensile Dupuytren disease. A literature
review is performed on the prevalence of
multiple joint affection (the need), the
advantages of flexible treatment regimens with
simultaneous joint injections (the benefits), the
safety issues (the risks), and the comparison
with surgical treatment options in multi-strand
Dupuytren disease (the assessment). The results
are summarized as the current state of the art in
collagenase usage in Dupuytren, its limits in
severely affected hands, and the requirements
or future adjustments needed in the treatment
regime to address even severe Dupuytren
disease with the non-operative collagenase
treatment option.
METHODS
The literature review was started with a
literature search of the electronic database
PubMed and Medline. Search terms were
Dupuytren disease, collagenase, multiple
joints, prevalence, complications, surgery,
safety, finger contracture and its plurals or
synonyms. Inclusion criteria were set to
benefit the goal of this literature review.
Articles that present the results of scientific
levels 3 and higher (Centre of Evidence-Based
Medicine, CEBM) that address the questions of
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this independent review (goals) were included.
These goals were mentioned above at the last
paragraph of the introduction and focus on the
need, the benefits, possible risks and assessment
of flexible regimens and multiple joint
collagenase treatment options in severely
affected hands with Dupuytren disease. This
article is based on previously conducted studies
and does not involve any new studies of human
or animal subjects performed by the author.
RESULTS
On the prevalence of multiple joint affection in
Dupuytren disease, out of 296 articles as a result
of the literature search, 15 articles were selected
to illustrate the need and benefits for
optimization of the single joint and interval
multiple session injections of collagenase. On
the collagenase treatment in Dupuytren disease,
27 articles out of 100 search results were
included to review the options and safety
issues of adjusted collagenase treatment
regimens. Finally, these options and results
were weighed with surgical treatment after a
selected number of 21 articles in the search
results of 419.
DISCUSSION
Collagenase in Dupuytren: Current State
of the Art and Encountered Challenges
Yet incurable, treatment of Dupuytren disease is
primarily focused on contracture release to
regain finger motion and restore hand
function. In the last decade, non-surgical
collagenase treatment removed the monopoly
of cutting or removing the strands that cause
the contractures. The strength of this
innovative treatment method is that surgery is
avoided, recovery is fast, and the outcome is
reliable, with a lower degree of recurrence than
needle fasciotomy [33]. The clinical outcome is
comparable with surgery (fasciectomy), but
collagenase treatment provides a more rapid
recovery and is associated with fewer serious
adverse events [37, 38, 49].
However, a weakness of the collagenase
injection technique is the limit of single joint
treatment in one setting with monthly interval
repeats if needed to treat more joint
contractures. This single-shot injection
technique was introduced mostly due to
security measures. Toxic dosage limits were set
low as a precaution and injection sites were
limited to prevent severe immune response
such as swelling, hematoma, and lymfangitis.
Treatment Regimen and Its Limits
Collagenase treatment is usually performed on
an outpatient basis. The patient receives his
collagen injection on the first day. The second
day he returns for a finger manipulation in an
effort to break the strands by forcefully
extending the finger (usually under local
anesthesia) and fit the extension splint. The
hand will typically show edema to some extent
for 5–10 days; a certain amount of pain and
hindrance is expected for about 2 weeks [3].
After care is focused on the recovery of full
range of finger motion, which rarely indicates
physiotherapy. A night-time splint to
maintain full extension for at least 3 months is
advised. Collagenase injections need to be
planned strategically. The injection is
performed on the first day and as prescribed,
24 h later the manipulation. What’s more, the
0.58 mg collagen dose is injected in a single
site to address one ray in one session,
usually restricted to one joint contracture
(either metacarpophalangeal or proximal
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interphalangeal). If multiple ray treatment is
required, monthly returning infiltrations and
manipulations are needed until sufficient finger
motion is achieved and hand function has
returned to an acceptable level for the patient.
A final restriction is the safe zone: the distal
limit of injection sites is the basis of the first
phalanx. For safety reasons with respect to the
flexor tendon, more distal injections are not
advised. Therefore, distal interphalangeal joint
contractures may not be addressed.
In total, current treatment regimen with
collagenase may restrain surgeons and patients
from collagenase treatment in severe Dupuytren
disease with multiple extensive ray
contractures. Here, the treatment time with
recurrent recovery intervals extends the overall
recovery time as compared to surgery where all
contractures are usually addressed in 1 session.
Multiple treatment sessions are obviously a
potential burden to the patient and may
increase the total treatment cost. The
restrictions of the initially prescribed
collagenase algorithm are thus increasingly
challenged in order to extend its indications
and efficiency in severe Dupuytren disease.
Collagenase in Severe Dupuytren
Contractures: Pushing Boundaries
Experience with the collagenase treatment is
rapidly increasing. This is reflected in more
efficient treatment regimens. First, the
organizational issue of having 24 h in between
injection and manipulation has been modified.
Mickelson et al. [32] demonstrated in 2014 an
optional time span of 7 days in between both
sessions without compromising efficiency [23].
The finger extension procedure can be
performed the next day or on any occasion
within 1 week after the injection, whichever is
more convenient [32]. Second, the surgeons
experience has increased efficiency of the
procedures. Peimer et al. [35] demonstrated
that the number of injections per treated joint
significantly decreased. In the registration trials,
1.7 injections per joint were required and after
1 year of use, this was reduced to a maximal
efficiency of 1.08 injections [35]. More recent
data confirmed that most treated joints now
require only one injection [48].
However, Coleman et al. [10, 11]
demonstrated that many patients present with
more than one joint affected and therefore
require multiple injections. They calculated a
mean (standard deviation) number of affected
joints of 3 ± 2.2 in their intended to treat
population [11]. Multiple ray involvement is
seen in more than half of the hands [21, 25].
This means that in the current algorithm of
single joint treatment with monthly intervals
between injections, the majority of patients will
need to undergo multiple sessions in several
months. This withholds a lengthy treatment
and recovery burden to the patient. The
efficiency of collagenase in fixed proximal
interphalangeal joint contractures is equal if a
second injection session is needed after initial
metacarpophalangeal treatment, but the overall
treatment is longer [21]. This motivated clinical
researchers to explore the option of concurrent
multiple strand collagenase treatment in
Dupuytren disease to fulfill the important
unmet need in the commonly seen multiple
digit Dupuytren contractures.
Recent outcome studies report promising
results. Gaston et al. [20] demonstrated
successful concurrent double-dose injections in
one or two cords in a single session. Efficacy was
comparable with earlier reports and no adverse
events were reported, with the exception of skin
laceration in 22% [29]. Atroshi et al. [2] reported
promising outcomes in higher dosage injections
with a technique modification allowing
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multiple joint corrections in a single session.
Again, more skin tears were encountered (in
40%). It is unclear whether the double dose is
the cause of these skin lacerations or rather the
more significant contracture release is. Hence,
skin tears are also seen in needle fasciotomy,
without enzyme injection in 27% of the
patients [39]. Another option is to use the
whole bottle of collagenase clostridium
histolyticum (0.78 mg instead of 0.58 mg): this
was reported by Verheyden [45] as another
efficient way to increase the dosage and safely
treat multi-cord affections in a single session in
144 patients.
However, if multiple strand treatment is
considered, risks and benefits need to be
outweighed and scientific support for this
clinical research needs to be explored.
Risks
The risks of injecting collagenase are
predominantly injection-related and transient:
skin rupture, tendon rupture, swelling and
edema, hematoma, pain, lymfangitis, fever,
and pruritus [36]. Severe allergic reactions and
anaphylactic shock are possible but not one case
has been reported up until now. On the other
hand, antibodies to collagenase may develop
after several treatments, raising concerns about
safety and efficacy as a result of sensitization
from repeated exposures. The development of
recombinant enzyme treatment methods was
initially introduced for treating lysosomal
storage disorders. Now, the collagen-based
disorder of Dupuytren disease is treated with
the collagenase clostridium hystolyticum.
Although enzyme treatment may hence carry
the risk of immunological response certainly in
repeated long-term treatment logarithms, safety
findings and adverse event reports and surely
problems of immunogenicity remain mild in
general [5]. Gajendran et al. [19] reported good
results in a patient receiving 12 dosages in 15
injections over a 4-year period in 2014. They
compare the evolution and increasing
knowledge with the botulinum toxin injection
experience and future adjustments of the
formula to prevent blocking antibodies in
some patients may be required 1 day.
Benefits
If ascertained safe and efficient, treating two
joints simultaneously with collagenase
injections in a single session will obviously
benefit the patient and treating surgeon in
different ways. First, overall treatment time
will be reduced significantly. Treating two
joints in one session, means restoring motion
in at least one complete finger in a maximum
of one treatment week, where in two monthly
interval sessions, it would mean a total
treatment time of four to 6 weeks. What is
more, optimized injection techniques add to
this benefit. For instance, a y-type strand
causing more than one finger contracture can
be solved with strategic injections with even
more extensile corrections, in which more
fingers (including two to even six joints) are
addressed in a single treatment session [30].
This obviously precludes a lower working
incapacity for the patient with a lower
healthcare cost, implies less time to treat, and
higher patient satisfaction with immediate
results [10, 11]. On top of fewer treatment
sessions and faster rehabilitation, one must
also consider the benefit in more efficient
orthotic devices without secondary
adjustments, since every session changes the
configuration of the hand [31]. Furthermore, if
therapy is indicated after collagenase
treatment, as required in more severe
contractures mostly of interphalangeal joints,
the rehabilitation period will equally be
reduced as overall injection sessions [42].
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Last, the anatomical restriction of injection
sites that excludes the distal interphalangeal
joint contractures was sporadically challenged
in off-label use in limited cases by different
surgeons, including the author. These more rare
contractures can be successfully addressed with
a 0.1 mg injection in the lateral cord at the
proximal interphalangeal (PIP) joint.
Obviously, the increasing efficiency in
collagenase injections with fewer treatment
sessions and increased gain in finger motion
will benefit more patients suffering from severe
Dupuytren disease. This evolution may
therefore reduce the need for elaborate surgery
with its inherent risks in the more challenging
Dupuytren contractures.
Collagenase in Future Treatment Regime
for Dupuytren Disease
Collagenase now has become common practice
in numerous hand surgery practices for
Dupuytren treatment and its position in the
regimen is yet evolutionary [20, 47].
The optimization of collagenase injections
in Dupuytren contractures may reduce surgery
even more in the overall treatment regime.
Collagenase treatment can be extended to
more severe Dupuytren disease. In severely
affected hands, extensile surgery carries a
higher risk for complications in up to 46% of
the patients [8, 12, 14, 26, 28]. Digital nerve or
artery injuries are even 10 times more common
in recurrent disease than in primary surgery
[12, 17, 41].
Local health economic differences may
influence treatment regimes, although
generally the total social cost of collagenase
treatment of Dupuytren contracture is lower
than surgery [6, 9, 13, 31, 38, 40]. In countries
such as Belgium, where healthcare
reimbursement is limited to a number of
injections per hand after simple cost-benefit
analysis, the optimization of collagenase
injection techniques is essential to offer more
patients the option of enzymatic fasciotomy to
avoid or postpone surgery [38].
Recurrence risk after collagenase treatment is
not lower than in surgery, with similar reports
varying between 4% after 1 year to 47% in
5 years. These results are comparable with
recurrence reports in surgical outcome studies
with a variety of recurrence reports ranging
from 0 to 71%, depending on definition and
time of follow-up [7, 29, 34]. Surgical technique
does not influence recurrence rates, although
needle fasciotomy has a particularly high
recurrence [7, 44]. In recurrence after
collagenase treatment, repeat injections or
even surgery remain viable options to treat
recurrent contractures [16, 19].
CONCLUSIONS
Since the collagenase technique was introduced
in the treatment regime for Dupuytren disease,
experience has built, injection efficiency has
increased, and satisfaction of both patient and
surgeon is markedly high. For safety reasons,
single joint injections (single site) were initially
advised. Recently, exploratory studies on
multiple injection sites demonstrated
promising outcomes. Today, multiple joint
corrections in a single session and even
complete multiple digit treatment have
become an option. Collagenase injection
technique optimization is needed to limit the
time to treat, working incapacity, healthcare
costs, and burden of multiple repeated
treatment sessions. Ultimately, collagenase
treatment will preferably result in maximal
restoration of the hand function in minimal
numbers of treatment sessions, even in severe
Dupuytren disease. This may minimize the
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burden of surgery to treat the finger
contractures in Dupuytren disease, taken that
not any treatment will cure the patient
indefinitely and recurrent contractures are
highly prevalent.
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